Новый виток эволюции лекарственного лечения мезотелиомы плевры
https://doi.org/10.33667/2078-5631-2022-26-27-30
Аннотация
Долгое время цитостатическая терапия оставалась единственным методом лечения неоперабельной мезотелиомы плевры и добавление таргетной антиангиогенной терапии не позволяло увеличить продолжительность жизни более чем до 18 мес. В статье представлены обзор последних достижений лекарственного лечения мезотелиомы плевры и результаты исследования CheckMate‑743, которые стали переломным моментом в эволюции лекарственного лечения злокачественной неоперабельной мезотелиомы плевры.
Об авторах
Т. Д. Барболина
ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава России; ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А. И. Евдокимова» Минздрава России
Россия
Россия
Барболина Татьяна Дмитриевна, к. м. н., врач-онколог, н. с. онкологического отделения лекарственных методов лечения (химиотерапевтического) № 17; ассистент кафедры онкологии факультета постдипломного дополнительного образования
Москва
С. Г. Багрова
ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава России
Россия
Россия
Багрова Светлана Геннадьевна, к. м. н., врач-онколог, н. с. онкологического отделения лекарственных методов лечения (химиотерапевтического) № 1
Москва
Список литературы
1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–2644.
2. Kindler HL, Ismaila N, Armato SG III, et al: Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018; 36: 1343–1373.
3. Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3: 756–63.
4. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19: 370–3.
5. Dudek AZ, Wang X, Gu L, et al: Randomized phase 2 study of maintenance pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first line chemotherapy: Cancer and Leukemia Group B30901 (Alliance). Clin Lung Cancer 2020; 21: 553–561.
6. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25–30.
7. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97: 2791–7.
8. Castagneto B, Zai S, Dongiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005; 28: 223–6.
9. van Haarst JM, Baas P, Manegold Ch, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002; 86: 342–5.
10. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405–14.
11. Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma: Phase II Results from the Randomized,Placebo-Controlled LUME-Meso Trial. J Clin Oncol 2017; 35: 3591–600.
12. de Gooijer C. J., Baas P., Burgers J.A. Current chemotherapy strategies in malignant pleural mesothelioma. Transl. Lung Cancer Res. 2018, Oct. Vol. 7, N 5. P. 574–583.
13. Карпенко Т.Д. и др. Анализ экспрессии белка PD-L1 в клетках злокачественной мезотелиомы плевры. Российский онкологический журнал. 2018. Т. 23, № 1. С. 4–9.
14. Ettinger DS, Wood DE, Aiser DL, et al. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 1. 2021. National Comprehensive Cancer Network. Accessed January 15, 2021.
15. Lievense L.A., Sterman D.H., Cornelissen R., Aerts J.G. Checkpoint blockade in lung cancer and mesothelioma. Am J Respir Crit Care Med. 2017; 196: 274–282.
16. Zhang F., Gong W. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesotheli-oma: A meta-analysis. Int. Immunopharmacol. 2020; 83: 106481.
17. Cedrés S., Ponce-Aix S., Zugazagoitia J., SansanoI., Enguita A., Navarro-Mendivil A., Martinez-Marti A., Martinez P., Felip E. Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) PLoS ONE. 2015; 10: e0121071.
18. Arnaud Scherpereelet, Julien Mazieres, Laurent Greillier, Sylvie Lantuejoul, Pascal Dô et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT‑1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019; 20 (3): e132.
19. Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res 2019; 25 (18): 5485–5492.
20. Josine Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries, Sjaak Burgers, Wieneke Buikhuisen et al. Programmed Death 1 Blockade with Nivolumab in Patients with Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology 2018; 13 (10): 1569–1576.
21. Evan W Alley, Juanita Lopez, Armando Santoro, Anne Morosky, Sanatan Saraf et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE‑028): preliminary results from a non-randomised,open-label, phase 1b trial. Lancet Oncol. 2017; 18 (5): 623–630.
22. Timothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE‑158 study. Lancet Respir Med. 2021; 9 (6): 613–621.
23. Popat S., Curioni-Fontecedro A., Dafni U., Shah R., O’Brien M. et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial. Ann Oncol. 2020; 31 (12): 1734–1745.
24. Maio M., Scherpereel A., Calabrò L., Aerts J., Cedres S. et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017; 18 (9): 1261–1273.
25. Calabrò L., Rossi G., Morra A., Rosati C., Cutaia O. et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO‑1 study. Lancet Respir Med 2021; 9 (9): 969–976.
26. Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF, van der Noort V, Harms E, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019; 7 (3): 260–270.
27. Baas P., Scherpereel A., Nowak A, Fujimoto N, Peters S. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397 (10272): 375–386.
28. Abdel-Rahman O., Elsayed Z., Mohamed H., Eltobgy M. Radical multimodality therapy for malignant pleural mesothelioma. Cochrane Database Syst Rev. 2018; 1 (1): CD012605.
29. Friedberg JS, Culligan MJ, Tsao AS, et al. A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol 2019; 14: 1343–53.
30. Gomez DR, Rimner A, Simone CB II, et al. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol 2019; 14: 1172–83.
31. Steven G. Gray, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res 2020; 9 (Suppl 1): S100–119.
Рецензия
Для цитирования:
Барболина Т.Д., Багрова С.Г. Новый виток эволюции лекарственного лечения мезотелиомы плевры. Медицинский алфавит. 2022;(26):27-30. https://doi.org/10.33667/2078-5631-2022-26-27-30
For citation:
Barbolina T.D., Bagrova S.G. New stage in evolution of drug treatment of pleural mesothelioma. Medical alphabet. 2022;(26):27-30. (In Russ.) https://doi.org/10.33667/2078-5631-2022-26-27-30
Просмотров:
441
Послать статью по эл. почте 